What it is
SS-31, also known as elamipretide or MTP-131, concentrates near the inner mitochondrial membrane and is researched for cellular energy, mitochondrial stress, exercise tolerance, and healthy-aging protocols.
Mechanism of action
SS-31 binds cardiolipin, a phospholipid that helps organize the inner mitochondrial membrane and electron transport chain. Stabilizing cardiolipin-dependent structure may support ATP production and reduce mitochondrial reactive oxygen species.
Evidence summary
Elamipretide has clinical research in primary mitochondrial myopathy and an FDA-approved prescription form for Barth syndrome. Pantheon customer-facing protocols should still be treated as educational and clinician-guided.
Typical dosing protocols
- 10 mg vial: 2.0 ml BAC water; 40-100 units delivers 2-5 mg
- 40 mg vial: 2.0 ml BAC water; 10-25 units delivers 2-5 mg
- 5 days on / 2 days off for 4-8 weeks; morning or pre-workout timing is common
Side effects & safety
- Injection-site redness, stinging, tenderness, itching, or mild swelling
- Headache, nausea, dizziness, lightheadedness, or temporary fatigue
- Rare allergic or cardiovascular symptoms should be treated as stop-and-seek-care signals
Cited studies
- (2025). DailyMed FORZINITY (elamipretide) prescribing information. DailyMed.Read source โ
- Karaa A, Haas R, Goldstein A, et al. (2023). Efficacy and Safety of Elamipretide in Primary Mitochondrial Myopathy, MMPOWER-3. Neurology.PMID 37268435Read source โ
- Karaa A, et al. (2020). A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy. Mitochondrion.Read source โ
- (2024). Elamipretide: structure, mechanism of action, and therapeutic potential review. Review.Read source โ
All content is for research and educational purposes. Peptides described are sold for laboratory research use only and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any protocol.